Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.

1 report, 0 independent Updated Jul 6

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Revolution Medicines (United States)Summit Therapeutics

Keep exploring

Part of

Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies. All 1 developments

The entities involved

Revolution Medicines (United States)
company in Redwood City, United States

Nothing else this week.
Summit Therapeutics
biopharmaceutical company

Nothing else this week.

Related events

daraxonrasib received Breakthrough Therapy Designation from the FDA for metastatic pancreatic ductal adenocarcinoma.Jun 8

Coverage

Newest first; wire copies grouped

Jul 6Unknown outlet